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The role of dopamine receptors in the modulation of nucleus
accumbens noradrenaline release was investigated in super-
fused rat brain slices. At concentrations of #1 mM, dopamine
enhanced, whereas at higher concentrations dopamine inhib-
ited electrically evoked [3H]noradrenaline release. The D1 re-
ceptor agonist SKF-38393 increased, whereas the D2 agonist
quinpirole inhibited evoked [3H]noradrenaline release. These
effects were attenuated by the D1 antagonist SCH-23390 and
the D2 antagonist (2)-sulpiride, respectively, indicating that
accumbens noradrenaline release is regulated by stimulatory
D1 and inhibitory D2 receptors. Whereas (2)-sulpiride en-
hanced, SCH-23390 did not reduce evoked accumbens
[3H]noradrenaline release, indicating a tonic activation of D2
receptors only. Given the similar apparent affinity of dopamine
for D1 and D2 receptors in striatal slices, the lack of tonic D1
receptor activation suggests that D1, unlike D2, receptors are
extrasynaptically localized. No dopaminergic modulation of
noradrenaline release was observed in rat medial prefrontal
cortex or amygdala slices. To examine the regulation of accum-
bens noradrenaline release under conditions of increased do-
paminergic activity, measurements were made using slices of
amphetamine-pretreated rats. In these slices, the electrically
evoked release of [3H]dopamine and [3H]noradrenaline was
enhanced. The increasing effect of (2)-sulpiride on noradrena-
line release was augmented, and SCH-23390 almost com-
pletely reversed this enhancement of [3H]noradrenaline release.
These data suggest that whereas although under a moderate
dopaminergic tone, accumbens noradrenaline release is mainly
regulated by inhibitory D2 receptors, under circumstances of
increased dopaminergic activity, recruitment of extrasynaptic
stimulatory D1 receptors contributes to enhancement of nor-
adrenaline release.
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Because of extensive and reciprocal connections with limbic and
motor systems, the nucleus accumbens (NAcc) is thought to be
important for the generation of motor responses to emotionally
relevant environmental stimuli (Mogenson, 1987; Kalivas et al.,
1993). The dopaminergic projection from the ventral tegmental
area to the NAcc, part of the so-called mesolimbic dopamine
(DA) system, has received particular attention in this respect. For
instance, NAcc DA neurotransmission has been shown to be
involved in exploratory behavior, in the psychomotor and rein-
forcing effects of drugs of abuse, and in appetitive and prepara-
tory behaviors. This has led to the general assumption that the
mesolimbic DA system plays a key role in goal-directed and
motivational behavior (Le Moal and Simon, 1991; Phillips et al.,
1991; Koob, 1992; Amalric and Koob, 1993; Salamone, 1994;
Schultz et al., 1997).
Interactions between the various inputs into the NAcc can be
expected to serve to optimize information flow necessary for the
generation of adaptive motor responses. In this respect, it has
been shown recently that the shell portion of the NAcc receives a
dense noradrenaline (NA)-containing projection, originating pri-
marily in the nucleus tractus solitarius (NTS) (Berridge et al.,
1997; Delfs et al., 1998). Because there is very little information
on the possible interaction between NAcc NA and DA systems
(Nurse et al., 1984; Yavich et al., 1997), we investigated here the
role of DA receptor stimulation on electrically evoked NA release
from rat NAcc slices in vitro.
Extracellular concentrations of NAcc DA and NA are en-
hanced by systemically and locally applied psychostimulant drugs,
such as amphetamine and cocaine (Di Chiara and Imperato,
1988; Seiden et al., 1993; McKittrick and Abercrombie, 1997;
Reith et al., 1997), and psychostimulant-induced locomotion is
known to rely on increases in NAcc DA neurotransmission (Kelly
et al., 1975; Pijnenburg et al., 1975; Delfs et al., 1990; Amalric and
Koob, 1993). In addition, involvement of NA in the psychomotor
effects of amphetamine and cocaine has also been demonstrated
(Snoddy and Tessel, 1985; Dickinson et al., 1988; Harris et al.,
1996). With regard to repeated exposure to psychostimulants,
there is ample evidence that this causes NAcc DA nerve termi-
nals to become hypersensitive (Kalivas and Stewart, 1991; Nestby
et al., 1997; Pierce and Kalivas, 1997). If NAcc NA neurotrans-
mission is modulated by DA, this regulation might be altered as
a result of psychostimulant-induced increase in DA tone. There-
fore, we also investigated the effects of DA receptor activation on
NA release in NAcc slices of rats repeatedly treated with amphet-
amine. This is of particular interest given the notion that the
neuroadaptations occurring after repeated psychostimulant expo-
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sure are involved in drug-induced addiction and psychosis (Rob-
inson and Becker, 1986; Robinson and Berridge, 1993).
MATERIALS AND METHODS
Animals and drug pretreatments. All experiments were approved by the
Animal Care Committee of the Free University of Amsterdam. Male
Wistar rats (Harlan CPB, Zeist, The Netherlands), weighing 180–200 gm
at the time of arrival in the laboratory, were housed two per cage in
Macrolon cages under controlled conditions (lights on from 7:00 A.M. to
7:00 P.M.) for 1 week before use. Food and water were available ad
libitum. Animals receiving drug pretreatment were briefly handled on the
2 d preceding the beginning of treatment. Pretreatment consisted of
intraperitoneal injections with 2.5 mg/kg (1)-amphetamine or saline,
administered once daily on 5 consecutive days. Three days after the last
injection, the animals were killed, and neurotransmitter release was
determined as described below.
Determination of neurotransmitter release. Rats were decapitated, their
brains were rapidly removed, and NAcc (including core and shell),
medial prefrontal cortex, or amygdala were dissected from a 1-mm-thick
coronal slice using the atlas of Paxinos and Watson (1986). Slices (0.3 3
0.3 3 1 mm) were prepared using a McIlwain tissue chopper and
incubated and superfused as described previously (Schoffelmeer et al.,
1994). Briefly, slices were washed twice with Krebs’–Ringer’s bicarbon-
ate medium containing (in mM) 121 NaCl, 1.87 KCl, 1.17 KH2PO4 , 1.17
MgSO4 , 1.22 CaCl2 , 25 NaHCO3 , and 10 D-(1)-glucose and subse-
quently incubated for 15 min in this medium under a constant atmo-
sphere of 95% O2–5% CO2 at 37°C. After preincubation, the slices were
rapidly washed and incubated for 15 min in 2.5 ml of medium containing
5 mCi of [ 3H]NA or, in one set of experiments, 5 mCi of [ 3H]DA under
an atmosphere of 95% O2–5% CO2 at 37°C. Because the brain areas
investigated have both dense dopaminergic and noradrenergic innerva-
tions, 1 mM GBR-12909 was added to the medium during incubation to
prevent accumulation of [ 3H]NA in DA nerve terminals, or 3 mM desi-
pramine was added during incubation to prevent accumulation of
[ 3H]DA in NA nerve terminals. After labeling, the slices were rapidly
washed and transferred to each of 24 chambers of a superfusion appa-
ratus (;4 mg of tissue in 0.2 ml of volume) and superfused (0.20 ml/min)
with medium gassed with 95% O2–5% CO2 at 37°C. The superfusate was
collected as 10 min samples after 40 min of superfusion (t 5 40 min).
Ca 21-dependent neurotransmitter release was induced during superfu-
sion by exposing the slices to electrical biphasic block pulses (1 Hz, 10
mA, 2 msec pulses to evoke release of [ 3H]NA, and 1 Hz, 30 mA, 2 msec
pulses to evoke release of [ 3H]DA) for 10 min at t 5 50 min (electrical
field stimulation). (2)-Sulpiride or SCH-23390 were added 30 min be-
fore, and DA, SKF-38393, quinpirole, or N 6-cyclopentyladenosine
(CPA) were added 20 min before electrical field stimulation. In the
experiments investigating the effects of DA on [ 3H]NA release, 3 mM
desipramine was present during superfusion to prevent uptake of DA
into noradrenergic nerve terminals. Drugs remained present until the
end of the experiment. In each experiment, quadruplicate observations
were made.
Calculation of release data. The radioactivity remaining at the end of
the experiment was extracted from the tissue with 0.1N HCl. The
radioactivity in superfusion fractions and tissue extracts was determined
by liquid scintillation counting. The efflux of radioactivity during each
collection period was expressed as a percentage of the amount of radio-
activity in the slices at the beginning of the respective collection period.
The electrically evoked release of neurotransmitter was calculated by
subtracting the spontaneous efflux of radioactivity from the total overflow
of radioactivity during stimulation and the next 10 min. A linear decline
from the 10 min interval before to the 20–30 min after the start of
stimulation was assumed for calculation of the spontaneous efflux of
radioactivity. The release evoked was expressed as percentage of the
content of radioactivity of the slices at the start of the stimulation period.
Effects of drugs were calculated as percentages of control and analyzed
using one-way ANOVA and, where appropriate, followed by Student–
Newman–Keuls tests. Curve fitting was done by nonlinear regression
analysis.
Radiochemicals and drugs. [ 3H]Noradrenaline (39 Ci/mmol) and
[ 3H]dopamine (47 Ci/mmol) were purchased from the Radiochemical
Center (Amersham, Buckinghamshire, UK). DA and (2)-sulpiride were
purchased from Sigma (St. Louis, MO), and SKF-38393, SCH-23390,
quinpirole, GBR-12909, and CPA were purchased from Research Bio-
chemicals (Natick, MA). Desipramine was a gift from Ciba-Geigy (Basel,
Switzerland). (1)-Amphetamine-sulfate was purchased from O.P.G.
(Utrecht, The Netherlands) and dissolved in sterile saline.
RESULTS
DA modulates NAcc NA release through stimulatory
D1 and inhibitory D2 receptors
DA had a biphasic effect on the electrically evoked [3H]NA
release (F(6,142) 5 10.78; p , 0.001). A concentration of 0.3 mM
slightly increased and 1 mM significantly increased the evoked
release of [ 3H]NA from superfused rat NAcc slices by ;15%. At
a concentration of 3 mM, DA had no effect on [ 3H]NA release,
and at 10 and 30 mM, DA appeared to suppress the electrically
evoked release of [3H]NA by 20–25% (Fig. 1).
To investigate the contribution of D1 and D2 receptors to the
effects of DA on [ 3H]NA release, selective D1 and D2 agonists
and antagonists were applied. The DA D1 agonist SKF-38393
dose-dependently increased electrically evoked [3H]NA release
(F(5,46) 5 7.06; p , 0.0001). The maximal effective concentration
of SKF-38393 (1 mM) caused an increase of [ 3H]NA release of
;35% above control (Fig. 2A). In contrast, the evoked release of
[ 3H]NA was dose-dependently inhibited by the D2 agonist quin-
pirole (F(5,63) 5 14.52; p , 0.0001); a 40% inhibition was ob-
served at a concentration of 1 mM quinpirole (Fig. 2B). When the
effects of the D1 and D2 antagonists SCH-23390 and (2)-
sulpiride, respectively, were tested, it appeared that 0.3 mM SCH-
23390 tended to increase [ 3H]NA release by ;10% (F(1,53) 5
3.74; p 5 0.06) (Fig. 2C). (2)-Sulpiride potently increased evoked
[3H]NA release, with a 65% increase above control values
observed with 1 mM (2)-sulpiride (F(1,39) 5 109.00; p , 0.0001)
(Fig. 2C).
Consistent with the previous experiment, 1 mM SKF-38393
increased electrically evoked [ 3H]NA release by 33%, whereas 1
mM quinpirole suppressed it by 32% (Fig. 3, lef t). In the presence
of 0.3 mM SCH-23390, the increasing effect of SKF-38393 on
[ 3H]NA release was significantly attenuated, from 33% in the
absence of to 10% in the presence of respective control values of
Figure 1. Effect of DA on the electrically evoked release of [ 3H]NA from
superfused slices of rat NAcc. The slices were superfused in the presence
of 3 mM desipramine to prevent uptake of DA into noradrenergic nerve
terminals and were stimulated electrically at t 5 50 min for 10 min. DA
was added to the superfusion medium 20 min before depolarization.
Control [ 3H]NA release, in the presence of 3 mM desipramine, amounted
to 5.8 6 0.4%. The data, expressed as percent of control release, represent
means 6 SEM of 24 observations. *p , 0.05 compared with control values
(Student–Newman–Keuls test).
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SCH-23390 (F(1,37) 5 15.53; p , 0.001) (Fig. 3, middle). In
contrast, 0.3 mM SCH-23390 did not at all affect the effect of
quinpirole on electrically evoked [3H]NA release; in both the
absence and presence of SCH-23390, 1 mM quinpirole inhibited
[ 3H]NA release by 32% (F(1,35) 5 0.02; NS) (Fig. 3, middle).
Exactly the opposite effect was found with (2)-sulpiride. In a
concentration of 1 mM, (2)-sulpiride significantly antagonized the
inhibitory effect of quinpirole on evoked [3H]NA release; the
decrease in [3H]NA release induced by quinpirole was 32% in the
absence of and 11% in the presence of (2)-sulpiride (F(1,26) 5
11.65; p , 0.01) (Fig. 3, right). In contrast, the increase in [ 3H]NA
release induced by SKF-38393 was not affected by (2)-sulpiride
(F(1,27) 5 0.28; NS) (Fig. 3, right).
In the presence of 1 mM (2)-sulpiride, DA potently increased
electrically evoked [3H]NA release (F(5,91) 5 7.85; p , 0.0001).
The dose–effect curve of DA was shifted leftward, as apparent
from the finding that the lowest concentration of DA to signifi-
cantly increase NA release was decreased from 1 mM to 30 nM. In
addition, the dose–response curve of DA was also shifted upward,
because the maximal effect of DA was increased from 15% in the
absence of to 35% in the presence of (2)-sulpiride (Fig. 4). It
should be noted that the increase in [ 3H]NA release induced by
DA in the presence of (2)-sulpiride was of a similar magnitude as
that induced by SKF-38393 (compare Figs. 2A, 4). Experiments
on the effects of DA in the presence of SCH-23390 yielded
inconsistent results, probably because of the fact that the selec-
tivity of SCH-23390 for D1 over D2 receptors in brain slices is
less than 10-fold (Plantje´ et al., 1984). Indeed, concentrations of
SCH-23390 .0.3 mM caused a marked enhancement of [ 3H]NA
release (data not shown), as observed with (2)-sulpiride.
The effects of D1 receptor stimulation on NAcc NA
release are not secondary to extracellular conversion
of cAMP to adenosine
Stimulation of D1 receptors enhances adenylate cyclase activity
(Stoof and Kebabian, 1984). It has been described recently that
certain effects of D1 receptor stimulation are the consequence of
extracellular conversion of cAMP to adenosine, which, through
stimulation of adenosine A1 receptors, alters neuronal activity
(Bonci and Williams, 1996; Harvey and Lacey, 1997). To investi-
gate whether the effect of D1 receptor activation on NAcc
[3H]NA release was caused by such a mechanism, the effect of the
adenosine A1 agonist CPA was investigated. CPA did not mimic
the effect of SKF-38393. On the contrary, CPA appeared to
suppress the electrically evoked [3H]NA release by 13% at a
concentration of 0.1 mM and by 19% at a concentration of 1 mM
(F(2,33) 5 5.67; p , 0.01; data not shown).
Figure 2. Effects of the D1 agonist SKF-38393 (A), the D2 agonist quin-
pirole (B), the D1 antagonist SCH-23390 (C; hatched bar), and the D2
antagonist (2)-sulpiride (cross-hatched bar) on the electrically evoked re-
lease of [ 3H]NA from superfused slices of rat NAcc. The slices were
superfused and stimulated electrically at t 5 50 min for 10 min. SKF-38393
and quinpirole were added to the superfusion medium at 20 min, and
SCH-23390 and (2)-sulpiride were added 30 min before depolarization.
Control [ 3H]NA release amounted to 4.7 6 0.3%. The data, expressed as
percent of control release, represent means 6 SEM of 8–28 observations.
*p , 0.05 compared with control values (Student–Newman–Keuls test);
**p , 0.001 compared with control values (ANOVA).
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DAergic regulation of NA release does not occur
within medial prefrontal cortex and amygdala
Regulation by DA of NA release has been reported previously to
occur in the hypothalamus (Misu et al., 1985) and hippocampus
(Jackisch et al., 1985), but, in those areas only a D2-mediated
inhibition of NA release was found. To investigate whether the
opposite regulation of NA release by D1 and D2 receptors also
occurred in other limbic areas, we studied the effects of SKF-
38393 and quinpirole on NA release in slices of medial prefrontal
cortex and amygdala. In slices of medial prefrontal cortex, 1 mM
SKF-38393 slightly, but not significantly (12% above control),
increased electrically evoked [3H]NA release (F(1,23) 5 2.17; NS).
Quinpirole, at a concentration of 1 mM, did not affect medial
prefrontal cortex [3H]NA release (F(1,23) 5 0.05; NS) (Fig. 5, lef t).
In rat amygdala slices, SKF-38393 (1 mM) did not at all affect
electrically evoked [3H]NA release (F(1,23) 5 0.04; NS), whereas
Figure 3. Effect of 0.3 mM SCH-23390 (middle) and 1
mM (2)-sulpiride (right) on the quinpirole-induced de-
crease and the SKF-38393-induced increase of electri-
cally evoked [ 3H]NA release in superfused rat NAcc
slices. The slices were superfused and stimulated elec-
trically at t 5 50 min for 10 min. SCH-23390 or (2)-
sulpiride were added 30 min before depolarization, and
SKF-38393 or quinpirole were added to the superfusion
medium at 20 min before depolarization. Control
[ 3H]NA release amounted to 4.7 6 0.3% of total tissue
radioactivity in the absence of antagonists, 5.1 6 0.3% in
the presence of SCH-23390, and 7.7 6 0.5% in the
presence of (2)-sulpiride, respectively. Data, expressed
as percent of respective control release, represent
means 6 SEM of 24 observations. Open bars represent
[ 3H]NA release under control conditions, hatched bars
represent release in the presence of 1 mM quinpirole, and
cross-hatched bars represent release in the presence of 1
mM SKF-38393. *p , 0.05; **p , 0.001 compared with
control values; ##p , 0.001 compared with same con-
dition without antagonist (ANOVA).
Figure 4. Effect of DA in the absence (compare with Fig. 1; open circles)
and in the presence of 1 mM (2)-sulpiride (closed circles) on the electri-
cally evoked [ 3H]NA release of superfused rat NAcc slices. The slices
were superfused in the presence of 3 mM desipramine to prevent uptake
of DA into noradrenergic nerve terminals and were stimulated electrically
at t 5 50 min for 10 min. (2)-Sulpiride was added to the superfusion
medium at 30 min before depolarization, and DA was added at 20 min
before depolarization. Control [ 3H]NA release amounted to 5.8 6 0.4%
of total tissue radioactivity in the absence of and 7.2 6 0.5% in the
presence of (2)-sulpiride, respectively. Data, expressed as percent of
control release, represent means 6 SEM of 24 observations. *p , 0.05
compared with control values in the presence of (2)-sulpiride (Student–
Newman–Keuls test).
Figure 5. Effects of SKF-38393 (1 mM) and quinpirole (1 mM) on the
electrically evoked release of [ 3H]NA from superfused slices of rat medial
prefrontal cortex (MPFC; lef t) or amygdala (right). The slices were super-
fused and stimulated electrically at t 5 50 min for 10 min. SKF-38393 and
quinpirole were added to the superfusion medium at 20 min before
depolarization. Control [ 3H]NA release amounted to 4.1 6 0.3% in
medial prefrontal cortex slices and 3.0 6 0.2% in amygdala slices. Data,
expressed as percent of control release, represent means 6 SEM of 11–12
observations. Open bars represent [ 3H]NA release under control condi-
tions, hatched bars represent release in the presence of 1 mM quinpirole,
and cross-hatched bars represent release in the presence of 1 mM
SKF-38393.
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quinpirole (1 mM) caused a slight (12%) nonsignificant inhibition
of evoked [3H]NA release (F(1,22) 5 1.19; NS) (Fig. 5, right).
Altered modulation of NAcc NA release by DA in slices
of amphetamine-pretreated rats
In NAcc slices of amphetamine-pretreated animals, the electri-
cally evoked release of [3H]DA was augmented by 73% (F(1,15) 5
61.25; p , 0.0001) (Fig. 6A), and the electrically evoked [ 3H]NA
release was increased by 22% (F(1,23) 5 7.34; p , 0.05) (Fig. 6B).
Whereas in slices of saline-pretreated rats 1 mM (2)-sulpiride
caused a 46% increase in evoked NAcc [ 3H]NA release (data not
shown, but see Fig. 2C), in slices of amphetamine-pretreated rats,
1 mM (2)-sulpiride enhanced evoked [3H]NA release by 92%.
Thus, in the presence of 1 mM (2)-sulpiride, the relative enhance-
ment of evoked [3H]NA release in slices of amphetamine-
pretreated rats was 60% (F(1,45) 5 74.37; p , 0.0001) (Fig. 6C)
compared with 22% in the absence of sulpiride (Fig. 6B), indi-
cating enhanced D2 receptor activation in slices of amphetamine-
pretreated rats. SCH-23390 (0.3 mM) slightly enhanced evoked
[ 3H]NA release in NAcc slices of saline-pretreated animals, but
in slices of amphetamine-pretreated rats, SCH-23390 suppressed
[3H]NA release by 20% (data not shown). However, these data
cannot be interpreted unambiguously because 0.3 mM SCH-23390
may be expected to partially block D2 receptors (Plantje´ et al.,
1984). Therefore, the effect of SCH-23390 was investigated in the
presence of 1 mM (2)-sulpiride. Interestingly, under circum-
stances of D2 receptor blockade, 0.3 mM SCH-23390 appeared to
Figure 6. A, Electrically evoked release of [ 3H]DA from superfused NAcc slices of rats pretreated with amphetamine (5 3 2.5 mg/kg, i.p.; hatched bar)
or saline (open bar) 3 d after treatment. [ 3H]DA release amounted to 1.0 6 0.1% in slices of saline-pretreated rats. B, Electrically evoked release of
[ 3H]NA from superfused NAcc slices of rats pretreated with amphetamine (5 3 2.5 mg/kg, i.p.; hatched bar) or saline (open bar) 3 d after treatment.
[ 3H]NA release amounted to 4.1 6 0.2% in slices of saline-pretreated rats. C, Electrically evoked release of [ 3H]NA from superfused NAcc slices of rats
pretreated with amphetamine (5 3 2.5 mg/kg, i.p.; hatched bar) or saline (open bar) in the presence of 1 mM (2)-sulpiride 3 d after treatment. [ 3H]NA
release amounted to 6.0 6 0.3% in slices of saline-pretreated rats. D, Electrically evoked release of [ 3H]NA from superfused NAcc slices of rats
pretreated with amphetamine (5 3 2.5 mg/kg, i.p.; hatched bar) or saline (open bar) in the presence of 1 mM (2)-sulpiride and 0.3 mM SCH-23390 3 d
after treatment. [ 3H]NA release amounted to 7.8 6 0.4% in slices of saline-pretreated rats. NAcc slices were superfused and stimulated electrically at
t 5 50 min for 10 min. (2)-Sulpiride and SCH-23390 were added to the superfusion medium at 30 min before depolarization. Note that the data are
expressed as percent of respective control release in slices of saline-pretreated rats. The basic effects of (2)-sulpiride and SCH-23390 (Fig. 2C) are
therefore not shown. Data represent means 6 SEM of 8–23 observations. *p , 0.05; ***p , 0.0001 compared with saline pretreatment (ANOVA).
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diminish the increase in NAcc [ 3H]NA release after previous
amphetamine treatment to 15% (F(1,22) 5 6.20; p , 0.05) (Fig.
6D). Thus, SCH-23390 almost abolished the increase in electri-
cally evoked [3H]NA release observed in slices of rats preexposed
to amphetamine.
DISCUSSION
The present data demonstrate that NA release in the rat NAcc is
under the opposing influence of stimulatory DA D1 and inhibi-
tory DA D2 receptors. These NA release-modulatory DA recep-
tors are presumably localized on nerve terminals of NA neurons
originating in the NTS (Delfs et al., 1998). Although occurrence
of presynaptic receptors on central nerve terminals has indeed
been demonstrated (Fisher et al., 1994; Sesack et al., 1994; Hersch
et al., 1995), the involvement of indirect or transsynaptic regula-
tion of neurotransmitter release cannot be excluded, even in
superfused brain slices. It is therefore possible that DA indirectly
affects NAcc NA release through modulation of excitatory or
inhibitory neurotransmission. In this respect, electrophysiological
experiments have shown that, in the NAcc, stimulation of pre-
synaptic D1 receptors depresses both inhibitory and excitatory
transmission (Pennartz et al., 1992; Harvey and Lacey, 1996;
Nicola and Malenka, 1997, 1998), whereas activation of presyn-
aptic D2 receptors suppresses excitatory transmission (O’Donnell
and Grace, 1994). Microdialysis studies have shown that D1
receptor stimulation actually enhances NAcc GABA release,
whereas D2 receptor stimulation appears to inhibit glutamate
release in the NAcc (Kalivas and Duffy, 1997). Thus, some of
these data seem to fit with the present observations of stimulatory
effects of D1 receptors and inhibitory effects of D2 receptor
stimulation, but others do not. The present data can therefore not
be explained solely on the basis of DA effects on excitatory and
inhibitory inputs into the NAcc rather than direct DA effects on
NA varicosities. Neurotransmission-modulatory effects of D1 re-
ceptor stimulation may also be indirectly mediated by the release
of adenosine (Bonci and Williams, 1996; Harvey and Lacey,
1997), but the selective adenosine A1 receptor agonist CPA
appeared not to mimic the stimulatory effects of D1 receptor
stimulation but even slightly decreased NAcc [3H]NA release.
This suggests that, although release-inhibitory adenosine A1 re-
ceptors may be present on NAcc NA nerve terminals, the stimu-
latory effect of D1 receptor activation is not mediated indirectly
through activation of adenosine receptors. Together, although
possible indirect effects of D1 and D2 receptor stimulation cannot
be ruled out, it is most likely that the release-modulatory DA
receptors are located on NAcc NA varicosities.
With regard to the tonic activation of these DA receptors, the
D2 antagonist (2)-sulpiride strongly increased NAcc NA release,
whereas the D1 antagonist SCH-23390 did not reduce NA re-
lease. Thus, released endogenous DA tonically inhibits NAcc NA
release through stimulation of D2 receptors, whereas the stimu-
latory D1 receptors are not activated under the present in vitro
conditions. Because one of our previous studies showed that, in
superfused rat striatal slices, exogenous and endogenous DA
displays an identical apparent affinity to D1 and D2 receptors
(Schoffelmeer et al., 1994), differences in apparent affinity for DA
cannot account for these findings. A more likely explanation is
that D1 and D2 receptors are differentially located on or near NA
nerve terminals. We hypothesize that D2 receptors are located
near active zones formed by DA and NA nerve terminals,
whereas D1 receptors are located more distal from the site of DA
release (Fig. 7, top). Indeed, such a differential localization of D1
and D2 receptors is supported by ultrastructural studies indicat-
ing that NAcc D1 receptors are mainly localized extrasynaptically
(Smiley et al., 1994; Hersch et al., 1995; Caille´ et al., 1996),
whereas D2 receptors can be found near DAergic nerve terminals
(Fisher et al., 1994; Sesack et al., 1994; Hersch et al., 1995; Delle
Donne et al., 1996). Interestingly, voltammetric measurements of
synaptic DA efflux showed that extrasynaptic DA neurotransmis-
sion occurs in the NAcc (Garris et al., 1994) and that excitatory
signals can be conveyed by extrasynaptic D1 receptors activated
by released DA, diffusing up to 12 mM away from release sites
(Gonon, 1997). In the case of DA modulation of NAcc NA
release, this would imply that DA released from mesolimbic
neurons preferentially interacts with D2 receptors, located in the
vicinity of the site of release. D1 receptors, located further away,
might be stimulated in case of higher rates of release and/or
during later phases of neurotransmission by DA that has diffused
away from the synapse (Fig. 7, bottom). The biphasic effects of
exogenously applied DA, activating both D1 and D2 receptors
(Schoffelmeer et al., 1994), could be the consequence of such a
different role of D1 and D2 receptors. For instance, when low
concentrations of exogenous DA are applied, the possible inhib-
itory effect of this exogenous DA could be masked by the tonic D2
receptor-mediated inhibition of NA release, causing the D1
receptor-mediated increasing effect to prevail (Fig. 1). It is also
worth noting that, in the presence of (2)-sulpiride when DA will
only stimulate D1 receptors, the dose–response curve of DA was
shifted upward, as well as leftward, closely resembling the dose–
response curve of SKF-38393 (compare Figs. 4, 2A).
Both the medial prefrontal cortex and the amygdala represent
limbic brain areas that, similar to the NAcc, receive dense DA
and NA innervations (Ungerstedt, 1971; Moore and Bloom, 1978,
1979; Le Moal and Simon, 1991). However, [ 3H]NA release in
slices of these areas does not seem to be modulated by DA. A
possible explanation for this difference is that the NA projection
to the NAcc originates mainly in the NTS (Delfs et al., 1998),
whereas medial prefrontal cortex and amygdala receive a NA
innervation from the locus ceruleus (Ungerstedt, 1971; Moore
and Bloom, 1979). Similar phenomena have been observed with
regard to the modulation of NA release by opioid receptors,
which also seems to differ between different regions of origin
(Heijna et al., 1991). The present data add to a growing body of
evidence that NAcc NA release may be modulated in a unique
manner. For instance, we have shown recently that, unlike in most
other brain areas receiving NA input, NAcc NA release is not
under the inhibitory influence of a2-autoreceptors (Schoffelmeer
et al., 1998).
The physiological relevance of the opposite regulation of NAcc
NA release by D1 and D2 receptors remains to be elucidated.
Coordinated activity of NAcc NA and DA neurotransmission
may be necessary for adequate processing of motivational, vis-
ceral, and autonomic stimuli into behavioral responses (Le Moal
and Simon, 1991; Phillips et al., 1991; Salamone, 1994; Schultz et
al., 1997; Delfs et al., 1998). The subtle interregulation of NAcc
NA and DA release therefore suggests the existence of a cate-
cholaminergic fine-tuning mechanism modulating the generation
of adaptive behavioral responses. In this respect, it is of interest
to note that recent electrophysiological experiments have shown
that, while in the NAcc DA, via D1 receptors, inhibits both
excitatory and inhibitory transmission; NA, via a-receptors only
inhibited excitatory, but not inhibitory, transmission (Nicola and
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Malenka, 1998). This suggests that the balance of DA and NA
neurotransmission in the NAcc might determine whether excita-
tory or inhibitory input into NAcc neurons will prevail. In addi-
tion, the entwinement of NAcc DA and NA systems could be
involved in certain phenomena associated with drug abuse, such
as psychostimulant sensitization and opiate withdrawal (Harris
and Aston-Jones, 1994). In parallel to the effects on NAcc NA
release described here, administration of D2 agonists into the
NAcc shell has been shown to inhibit, and administration of a D1
agonist has been shown to enhance naloxone-evoked opiate with-
drawal effects, whereas an intra-NAcc D2 antagonist appeared to
evoke opiate withdrawal phenomena (Harris and Aston-Jones,
1994). Because increased NA activity accompanies opiate with-
drawal (Akaoka and Aston-Jones, 1991; De Vries et al., 1993), it
is likely that the effects of intra-NAcc-applied DAergic drugs on
opiate withdrawal involve modulation of NAcc NA release.
In NAcc slices of amphetamine-pretreated rats, the electrically
evoked release of both [ 3H]NA and [ 3H]DA was enhanced.
Moreover, the increase in [ 3H]NA release induced by D2 recep-
tor blockade with (2)-sulpiride was enhanced, indicating an in-
crease in the tonic D2-mediated suppression of NA release.
Remarkably, SCH-23390 primarily antagonized this augmenta-
tion of NAcc NA release induced by amphetamine preexposure.
These data indicate that, under conditions of different dopami-
nergic tone in the accumbens, NA release is differentially regu-
lated by DA receptors. In addition, they are consistent with our
hypothesis that D1 receptors represent extrasynaptic receptors,
particularly stimulated under conditions of increased DA release.
Thus, under circumstances of moderate DA tone, released DA,
stimulating D2 receptors, tonically suppresses NAcc NA release,
whereas extrasynaptically located D1 receptors play a less prom-
inent role in the regulation of NA release (Fig. 7, top). When DA
tone is increased, such as in amphetamine-pretreated rats, en-
hanced DA release from mesolimbic terminals increases the tonic
D2-receptor-mediated suppression of NA release. In addition,
augmented DA release will also stimulate extrasynaptic D1 re-
ceptors, resulting in a net increase in NAcc NA release (Fig. 7,
bottom). Assuming that the balance between NAcc DA and NA
activity is relevant for the formation of adequate adaptive behav-
ioral responses, this amphetamine-induced disbalance in cate-
cholamine neurotransmission could represent a substrate for the
distorted motivational and affective behaviors characteristic for
drug-induced addiction and psychosis.
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